{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 46,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes detailed source citations in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/8",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Clinical efficacy comparison charts for STS and Colorectal Cancer",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e22231f-92f4-4466-bda9-9afe14d7b894",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.22,
        "x": 0.75,
        "y": 0.15
      },
      "kind": "list",
      "text": "IMX-110 category leading progression free survival (PFS) in heavily pretreated patients with zero drug-related SAEs. IMX-110 100% Disease Control at 2 months. IMX-110 treated STS patients had 3-13 median prior lines of therapies. IMX-110 + PD-1 treated r/r colorectal cancer showed 75% tumor shrinkage and mPFS not reached (NR) at 2 months in patients had 8 median prior lines of therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfa3d1c5-a6c2-4b70-a700-f80142083125",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Note: mPFS is Median Progression Free Survival... [detailed citations]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7025ccc-04e6-41bc-98e8-d5ecf848e941",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMX-110 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Soft Tissue Sarcoma (STS), and Encouraging Efficacy in Colorectal Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3020c33-a0a6-4059-9548-9dab1fca5c8b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "5027be93-535f-449a-9c55-44f893156c27",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation highlights the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5f2e0111-b5c3-4127-8874-dd9c86260d92",
      "evidence": "The presentation highlights the market opportunity and the limitations of current treatments.",
      "position": 0,
      "objective": "What are the consequences of not addressing the unmet medical needs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}